Sorafenib, a clinically approved kinase inhibitor attenuates Streptococcus pneumoniae pathogenesis in vivo by targeting serine/threonine kinase StkP
Joel Abraham, Aswathy C. Sagilkumar, Himani Dhyani, Charmi M. Panchal, Shaheena Aziz, M K Priyadatha, Aan Ruth, K BHASKARAN, Sivakumar Krishnankutty Chandrika, S. Shaima, Rosemol Varghese, Ayyanraj Neeravi, Balaji Veeraragavan, Nagarjun Narayanaswamy, Sandhya Ganesan, Karthik Subramanian
This study shows that sorafenib, a cancer drug, targets StkP in Streptococcus pneumoniae, reducing bacterial pathogenesis and mortality in mice.
mBio · Jun 16, 2026Peer-reviewedMicrobiology